Fact-checked by Grok 2 weeks ago

ATP-sensitive potassium channel

ATP-sensitive potassium channels (KATP channels) are inwardly rectifying channels that sense intracellular ATP levels to couple cellular to excitability, opening primarily when ATP concentrations fall to hyperpolarize the cell and reduce firing. First discovered in 1983 through patch-clamp recordings in cardiac myocytes, these channels exhibit a single-channel conductance of 70–80 pS in symmetrical conditions and are inhibited by ATP with a Ki of 10–500 μM. Structurally, KATP channels form hetero-octameric complexes consisting of four pore-forming Kir6.x subunits (Kir6.1 or Kir6.2) that create the central potassium-selective pore and four regulatory receptor (SUR) subunits (SUR1, SUR2A, or SUR2B) that encircle and modulate the core. The overall architecture, resolved by cryo-electron microscopy at ~5.6 Å resolution for the pancreatic isoform, measures approximately 160 × 160 × 130 Å and features a two-layer design with transmembrane and intracellular domains, where SUR subunits dock onto Kir6.2 via their TMD0-L0 linker to enable regulation. Isoform-specific assembly, such as Kir6.24/SUR14 in pancreatic β-cells or Kir6.24/SUR2A4 in cardiac myocytes, confers tissue-specific gating properties, including to Mg-ADP activation and inhibition. These channels are widely distributed across excitable tissues, including pancreatic β-cells, cardiomyocytes, vascular , , neurons, and endocrine cells. Physiologically, they serve as metabolic sensors: in pancreatic β-cells, elevated glucose raises ATP/ADP ratios to close KATP channels, depolarizing the to trigger insulin release; in the heart and brain, their activation during energy stress shortens action potentials, limits calcium influx, and conserves ATP to protect against ischemia or . Additional regulators include (PIP2), which promotes opening, and by protein kinases that fine-tunes activity. Dysfunction in KATP channels underlies several channelopathies, such as congenital and neonatal from mutations in ABCC8 (encoding SUR1) or KCNJ11 (encoding Kir6.2), and cardiac disorders such as and from mutations in ABCC9 (encoding SUR2) or KCNJ8 (encoding Kir6.1). Therapeutically, they are targeted by (e.g., glibenclamide, which binds SUR to close channels for glycemic control in ) and potassium channel openers (e.g., , which activates SUR for in ).

History and Discovery

Initial Identification

The ATP-sensitive potassium (KATP) channel was first identified in 1983 through electrophysiological recordings in cardiac myocytes. Using the cell-attached patch-clamp technique, Akinori Noma observed a novel potassium conductance that was inhibited by intracellular ATP concentrations in the millimolar range, distinct from other known K+ channels due to its sensitivity to metabolic state. This conductance increased upon metabolic inhibition with agents like dinitrophenol or , which deplete cellular ATP, suggesting a role in linking cellular energy levels to membrane excitability. In 1984, the channel was subsequently identified in pancreatic β-cells, where it was linked to the regulation of glucose-stimulated insulin secretion. Frances M. Ashcroft and colleagues, employing single-channel patch-clamp recordings on isolated rat pancreatic β-cells, demonstrated that elevating extracellular glucose led to the closure of ATP-sensitive K+ channels, resulting in membrane depolarization and subsequent insulin release. This observation built on the cardiac findings by highlighting the channel's responsiveness to changes in intracellular ratios driven by glucose metabolism. Early studies established the KATP channel's role as a metabolic sensor across excitable tissues, with its activity inhibited by physiological ATP levels (around 1-10 mM) but relieved under conditions of energy stress, such as or substrate deprivation. These discoveries relied on innovative patch-clamp methods, pioneered by Neher and Sakmann, which allowed direct measurement of single-channel currents, combined with metabolic inhibition protocols to manipulate levels and reveal the channel's biophysical properties.

Molecular Characterization

The molecular characterization of ATP-sensitive potassium (KATP) channels advanced significantly in the mid-1990s through the cloning and sequencing of their key subunits. Building on earlier electrophysiological observations from the 1980s that identified ATP-sensitive K+ conductances in pancreatic beta-cells, researchers cloned the pore-forming inward rectifier subunits Kir6.1 and Kir6.2. In 1995, Inagaki et al. isolated Kir6.1 from rat tissues including brain, revealing it as a member of the Kir family with two transmembrane domains and sequence similarity to other inward rectifiers, expressed in various tissues including heart and brain. Concurrently, Sakura et al. and Inagaki et al. cloned Kir6.2 from a mouse insulinoma cDNA library and rat pancreatic islets, respectively, demonstrating its high expression in beta-cells, brain, heart, and skeletal muscle, and its ATP-sensitive properties when expressed alone, though with low conductance. The regulatory sulfonylurea receptor (SUR) subunits were identified shortly thereafter, completing the core molecular identity of KATP channels. In 1995, Aguilar-Bryan et al. cloned SUR1 from a insulinoma cDNA library using expression cloning based on high-affinity binding, showing it as a large (approximately 140-170 kDa) with multiple transmembrane segments and nucleotide-binding folds, essential for modulating channel activity in pancreatic beta-cells. In 1996, Inagaki et al. cloned SUR2 from rat heart and , identifying splice variants SUR2A and SUR2B that differ in their C-terminal domains and confer tissue-specific pharmacological properties, such as sensitivity to MgADP and channel openers. Initial functional studies confirmed the heteromeric nature of KATP channels through co-expression in systems. Inagaki et al. demonstrated in 1995 that co-expression of Kir6.2 with SUR1 in COS cells or oocytes reconstituted functional KATP channels with properties matching native beta-cell channels, including inhibition by ATP and stimulation by . Subsequent work by Clement et al. in 1997 used tandem constructs and analysis in oocytes to establish the 4:4 of Kir6.x to SUR subunits, forming an octameric complex essential for proper trafficking and activity. Early molecular insights also linked KATP channel defects to . In 1996, Nestorowicz et al. identified mutations in Kir6.2 associated with familial persistent hyperinsulinemic of infancy (PHHI), a condition characterized by unregulated insulin secretion due to loss-of-function in beta-cell KATP channels. Similarly, Thomas et al. reported SUR1 mutations in PHHI patients in 1995, establishing the genetic basis for channelopathies affecting insulin regulation.

Molecular Structure

Kir6.x Pore-forming Subunits

The Kir6.x family comprises two principal isoforms, Kir6.1 and Kir6.2, encoded by the KCNJ8 and KCNJ11 genes, respectively. These proteins function as the pore-forming α-subunits of ATP-sensitive (KATP) channels, forming homotetramers or heterotetramers that constitute the central ion-conducting pore of the channel complex. Each subunit spans the membrane with two transmembrane helices, and , which together create the aqueous pore pathway selective for K+ ions. The selectivity filter, located at the extracellular end of the pore, features the conserved GYG motif typical of channels, with the sequence GFG in Kir6.x enabling high-fidelity K+ permeation while excluding other ions. The intracellular N- and C-termini of Kir6.x subunits project into the , forming a large cytoplasmic domain that houses key regulatory elements, including nucleotide-binding sites for ATP. Binding of ATP to residues such as R50 in the and K185 in the directly inhibits channel opening, conferring metabolic sensitivity to the . These termini also mediate inter-subunit interactions within the tetramer, stabilizing the overall architecture. Structural studies reveal that the Kir6.x tetramer adopts a inward-rectifier , with the M2 helices crossing at the intracellular gate in the closed state. In terms of tissue distribution, Kir6.2 predominates in pancreatic β-cells and cardiac myocytes, where it supports glucose-stimulated insulin secretion and cardioprotective responses, respectively. In contrast, Kir6.1 is the dominant isoform in vascular , contributing to vasoregulation. Expressed in isolation, Kir6.x subunits display weak inward due to intrinsic voltage-dependent by intracellular polyamines and Mg2+, but they exhibit poor plasma membrane trafficking owing to endoplasmic reticulum retention signals in their C-termini; co-assembly with SUR regulatory subunits is required for efficient surface expression and functional activity.

SUR Regulatory Subunits

The sulfonylurea receptor (SUR) subunits are integral regulatory components of ATP-sensitive potassium (KATP) channels, belonging to the ATP-binding cassette (ABC) transporter superfamily. Encoded by the ABCC8 gene for SUR1 and the ABCC9 gene for SUR2, these proteins feature a modular with 17 transmembrane domains (TMDs) organized into three bundles: TMD0 (five helices), TMD1 (six helices), and TMD2 (six helices). The cytosolic nucleotide-binding domains (NBD1 and NBD2) form the ABC core, where NBD1 and NBD2 bind nucleotides such as ATP and MgADP, with NBD2 exhibiting low-level activity essential for channel modulation. SUR subunits assemble with four Kir6.x pore-forming subunits to form an octameric KATP channel complex, primarily through interactions between the SUR TMD0 region and Kir6.x cytosolic domains. The regulatory functions of SUR subunits center on nucleotide-dependent modulation of channel gating. Binding of MgADP to the NBDs promotes NBD dimerization, which antagonizes ATP-induced channel closure and stimulates KATP activity, thereby linking cellular metabolism to ion conductance. SUR also serves as the primary binding target for pharmacological agents; sulfonylureas such as glibenclamide bind with high affinity to SUR1, inhibiting channel opening and reducing K+ efflux, a exploited in treatment. In contrast, potassium channel openers (PCOs) like interact with SUR to enhance channel activity by stabilizing open states, particularly through sites in the TMD1-TMD2 regions. Isoform-specific properties of SUR subunits confer tissue-selective channel behaviors. SUR1, predominantly expressed in pancreatic β-cells and neurons, exhibits high sensitivity to MgADP stimulation and , enabling precise metabolic sensing for insulin secretion regulation. SUR2A, a splice variant of SUR2 found in cardiac myocytes, displays lower MgADP sensitivity and reduced responsiveness to certain PCOs like , supporting cardioprotective roles during ischemia. SUR2B, the vascular variant, shows intermediate MgADP sensitivity and greater affinity for vasodilatory PCOs such as pinacidil, facilitating vascular tone control. These differences arise from variations in the C-terminal tails and NBD sequences, influencing and interactions.

Channel Assembly and Trafficking

The ATP-sensitive potassium (KATP) channel is assembled in the () as a hetero-octameric complex comprising four pore-forming Kir6.x subunits (either Kir6.1 or Kir6.2) and four regulatory receptor (SUR) subunits (SUR1, SUR2A, or SUR2B). This ensures functional coupling between the pore and regulatory components, with co-expression of Kir6.x and SUR being essential for forming active channels capable of ER exit.80321-9) Individual Kir6.x and SUR subunits contain ER retention motifs, such as the RKR sequence in the C-terminus of Kir6.2, which binds coat protein I (COPI) and prevents premature trafficking to the plasma membrane.80708-4) Assembly with SUR masks this RKR motif through direct subunit , releasing the retention signal and permitting anterograde from the ER.80708-4) Similarly, SUR subunits possess retention signals that are alleviated upon complex formation, highlighting the cooperative nature of assembly for . Post-assembly, the KATP complex undergoes processing in the Golgi apparatus, where SUR subunits acquire complex N-linked glycosylation, distinguishing mature channels from ER-retained precursors.66502-6/fulltext) Trafficking to the plasma membrane then depends on (PIP2), which stabilizes the channel at the and facilitates insertion, as depletion of PIP2 reduces surface expression. This lipid dependence underscores the role of membrane composition in directing final localization. Recent cryo-EM structures, such as the open-state pancreatic KATP at ~3 Å resolution (as of 2024), reveal detailed interactions at the Kir6.x-SUR and tandem PIP2 binding sites that stabilize the open pore. Quality control during biogenesis involves ER-associated (ERAD) of misfolded or unassembled complexes, mediated by the Derlin-1 protein and the p97/VCP, which retrotranslocate substrates for ubiquitination and proteasomal breakdown.65458-8/fulltext) Overexpression of Derlin-1 accelerates this , reducing channel surface density, while inhibition enhances efficiency.65458-8/fulltext) For mitochondrial KATP (mitoKATP) channels, may occur independently of full-length SUR subunits, potentially involving truncated Kir6.1 fragments targeted to the via alternative pathways. This SUR-independent configuration remains controversial but aligns with observed pharmacological and physiological differences from plasma membrane KATP channels.

Gating and Biophysical Properties

Nucleotide-dependent Gating

The nucleotide-dependent gating of ATP-sensitive potassium (KATP) channels is primarily governed by the inhibitory effects of ATP and the counteracting stimulation by , which together allow the channel to sense cellular energy status. ATP directly binds to the cytoplasmic of the pore-forming Kir6.x subunits, leading to channel closure without requiring nucleotide . This binding occurs at a site involving key residues such as K185, which interacts with the β-phosphate of ATP, and is selective for the moiety. The inhibitory concentration () for ATP on Kir6.2-containing channels typically ranges from 10 to 100 μM, with values around 175 μM observed for truncated Kir6.2 constructs and lower sensitivities (e.g., ~6-30 μM) for full Kir6.2/SUR1 complexes due to modulatory influences. In contrast, promotes channel opening by antagonizing ATP inhibition through interactions at the nucleotide-binding domains (NBDs) of the regulatory SUR subunits, a process that relieves the inhibitory effect of ATP on Kir6.x. This -mediated stimulation is markedly enhanced by Mg²⁺, forming Mg, which binds preferentially to the consensus NBD (NBD2) and, to a lesser extent, the degenerate NBD (NBD1) of SUR, inducing conformational changes that favor the open state. The role of SUR in conferring sensitivity is evident from studies showing that in SUR NBDs abolish this antagonism while preserving intrinsic ATP inhibition by Kir6.x alone. The open probability (Po) of KATP channels under nucleotide-dependent control can be approximated by the equation: P_o \approx \frac{1}{1 + \frac{[\text{ATP}]}{K_i}} where K_i is the inhibition constant for ATP, reflecting a simple inhibitory binding model. This gating mechanism exhibits voltage independence, as ATP inhibition persists equally across membrane potentials without alteration in K_i. Additionally, ATP binding displays , characterized by a Hill coefficient of approximately 2, indicating that multiple (likely two) ATP molecules interact to stabilize the closed state effectively.

Modulation by Metabolites and Drugs

Phosphatidylinositol 4,5-bisphosphate (PIP2) and other phospholipids play a crucial role in stabilizing the open state of ATP-sensitive potassium (KATP) channels by interacting directly with the Kir6.x pore-forming subunits, thereby reducing the channel's sensitivity to inhibitory ATP concentrations. This interaction enhances channel activity under physiological conditions, promoting metabolic sensing by counteracting ATP-dependent closure. Similarly, long-chain acyl-CoA esters act as potentiators of KATP channels, particularly in pancreatic and cardiac isoforms, by binding to sites that facilitate channel opening and amplify responses to metabolic signals. These esters, such as oleoyl-CoA, interact with PIP2-binding residues on Kir6.x, further shifting the channel toward an activated conformation. Intracellular acidosis directly activates KATP channels by protonation of specific residues, leading to increased channel conductance independent of ATP levels, which contributes to cellular protection during metabolic stress. This pH sensitivity is evident in excised patches where lowering pH to around 6.5 enhances activity, particularly in vascular and cardiac channels. Temperature also modulates KATP channel function, with higher temperatures accelerating activation kinetics by openers and altering the ATP dose-response curve, reflecting temperature-dependent conformational changes in the channel complex. Pharmacological modulation occurs primarily through the sulfonylurea receptor (SUR) subunit. Sulfonylureas, such as glibenclamide, bind to high- and low-affinity sites on SUR, promoting channel closure by stabilizing inhibitory interactions with Kir6.x and displacing stimulatory . In contrast, openers (PCOs) like pinacidil bind to distinct sites on SUR, antagonizing effects and enhancing channel opening, often by promoting SUR conformational changes that favor the active state. Mg-nucleotides exert allosteric stimulation of KATP channels via interactions with the nucleotide-binding domains (NBDs) of SUR, where Mg-ADP binding induces NBD dimerization, relieving tonic inhibition and increasing channel open probability. This mechanism complements direct ATP inhibition at Kir6.x, allowing fine-tuned responses to cellular energy states.

Localization and Isoforms

Plasma Membrane KATP Channels

Plasma membrane KATP channels are hetero-octameric complexes composed of four pore-forming Kir6.x subunits and four regulatory SUR subunits, which integrate into the of excitable cells to couple metabolic status to membrane excitability. These channels are predominantly expressed in tissues such as pancreatic beta cells, cardiomyocytes, neurons, and vascular cells, where they contribute to the of resting and dynamics. The assembly of these subunits occurs in the , with SUR facilitating the trafficking of the complex to the plasma membrane, including the in or the beta-cell plasma membrane. The specific isoform composition determines tissue-specific properties and localization. In pancreatic beta cells, the predominant form is the Kir6.2/SUR1 complex, which exhibits a single-channel conductance of approximately 70 under symmetrical potassium conditions and plays a key role in glucose-stimulated insulin secretion by hyperpolarizing the membrane during low ATP states. In cardiomyocytes, Kir6.2 pairs with SUR2A to form channels with conductances around 55-70 , enabling rapid hyperpolarization and shortening of action potentials in response to metabolic stress. Vascular smooth muscle cells primarily express Kir6.1/SUR2B channels, characterized by lower conductances of about 35-40 , which help maintain vascular tone by modulating excitability. These plasma membrane channels exhibit inward , allowing significant efflux at hyperpolarized potentials, which promotes membrane hyperpolarization and reduces excitability when intracellular ATP levels decrease. The differential expression of Kir6.1 versus Kir6.2 influences conductance and rectification properties, with Kir6.2-based channels generally showing higher conductance values compared to Kir6.1 variants. Trafficking to the plasma membrane is tightly regulated by SUR subunits, ensuring proper insertion and functional density in excitable membranes for precise control of .

Mitochondrial KATP Channels

Mitochondrial ATP-sensitive channels (mitoKATP), distinct from their counterparts, are channels embedded in the that respond to changes in ATP levels within the . These channels exhibit a smaller single-channel conductance, typically in the range of 10-30 pS under physiological gradients, compared to the larger conductances observed in sarcolemmal KATP channels. MitoKATP also display reduced sensitivity to ATP inhibition, with half-maximal inhibitory concentrations (IC50) often exceeding 1 mM from the matrix side, allowing them to remain responsive despite the high ATP concentrations in the , which protects them from cytosolic ATP fluctuations. This lower ATP affinity suggests a role in fine-tuning mitochondrial rather than rapid metabolic sensing like isoforms. The molecular composition of mitoKATP has been the subject of ongoing research. Earlier models proposed non-canonical assemblies involving fragments of Kir6.x and SUR subunits or multiprotein complexes including (SDH) and other inner membrane proteins. However, as of 2019, the pore-forming subunit was identified as the protein encoded by the (termed MITOK), and the regulatory subunit as the product of the ABC8 (MITOSUR), forming a structure analogous to but distinct from the plasma membrane Kir6/SUR octamer. This identification has been supported by subsequent studies, though tissue-specific variations and additional regulatory components continue to be investigated as of 2025. These channels retain pharmacological sensitivity to openers like and blockers like glibenclamide, consistent with their role in modulating mitochondrial function. Recent advances (2023–2025) have further elucidated mitoKATP functions, including control of structure and exercise capacity, as well as of brown adipocyte differentiation and , highlighting its conserved role in mitochondrial across tissues. MitoKATP channels are localized exclusively to the , where they contribute to and without direct exposure to cytosolic ATP due to the impermeability of the outer membrane. Their activity has been detected using specialized techniques adapted for mitochondrial studies, including patch-clamp recordings on mitoplasts (mitochondria with outer membrane removed) to measure single-channel currents under controlled ionic conditions. Complementary evidence comes from fluorescent methods, such as the uptake of -sensitive dyes (e.g., PBFI) or indicators like calcein-AM, which reveal channel-mediated swelling or fluxes in response to pharmacological modulators. These approaches have confirmed the channel's presence across species, including in cardiac and neuronal mitochondria, highlighting its conserved bioenergetic functions.

Physiological Functions

Metabolic Sensing in Pancreatic Beta Cells

In pancreatic beta cells, ATP-sensitive potassium (KATP) channels, formed by SUR1 regulatory and Kir6.2 pore-forming subunits, serve as key metabolic sensors that link nutrient availability to insulin secretion. Glucose enters beta cells via GLUT2 transporters and undergoes glycolysis and mitochondrial oxidation, elevating the intracellular ATP/ADP ratio. This increase in ATP directly inhibits KATP channel opening, leading to channel closure. Channel closure reduces K+ efflux, causing plasma membrane that activates voltage-gated Ca2+ channels. The resulting Ca2+ influx triggers Ca2+-dependent of insulin granules, initiating biphasic insulin release. This mechanism ensures precise coupling of insulin output to blood glucose levels, preventing hypo- or . KATP channels exhibit high open probability at low glucose (<3 mM), with half-maximal closure occurring around 3-5 mM glucose, which aligns with the threshold for the first phase of insulin secretion and provides rapid responsiveness to postprandial glucose rises. Long-chain acyl-CoA esters, generated during fatty acid metabolism, further modulate KATP activity by interacting with the SUR1 subunit. These metabolites reduce the channel's sensitivity to ATP inhibition, promoting channel opening and thereby counteracting glucose-induced closure to fine-tune insulin secretion under nutrient-rich conditions. This interaction occurs at a unique binding site on SUR1, distinct from nucleotide-binding domains, and may contribute to lipid-mediated regulation of beta cell excitability. Prolonged exposure to high glucose also influences KATP expression at the transcriptional level. Elevated glucose concentrations downregulate mRNA levels in isolated rat pancreatic islets by approximately 70%, likely through glucose-responsive transcriptional mechanisms that repress gene promoter activity. This adaptive downregulation may alter channel density over time, potentially modulating beta cell sensitivity to metabolic signals during chronic hyperglycemia.

Cardiovascular Protection

ATP-sensitive potassium (KATP) channels in the of cardiomyocytes, composed of the Kir6.2 pore-forming subunit and the SUR2A regulatory subunit (sarcKATP), play a critical role in cardioprotection during hypoxic conditions. Activation of these channels hyperpolarizes the , shortening the action potential duration and thereby reducing calcium influx through L-type calcium channels, which mitigates intracellular Ca2+ overload and contractile dysfunction. This mechanism conserves energy by decreasing ATP demand and preventing excessive excitation-contraction coupling during oxygen deprivation. Ischemic preconditioning, discovered in the late and linked to KATP channels in the , exemplifies their protective function, where brief episodes of ischemia followed by reperfusion confer tolerance to subsequent prolonged ischemia. During these short ischemic bouts, rising intracellular levels—due to metabolic stress—activate sarcKATP and mitochondrial KATP (mitoKATP) channels by relieving ATP inhibition, triggering downstream signaling cascades that limit infarct size and improve recovery. Seminal studies in the mid- demonstrated that pharmacological blockade of KATP channels abolishes this preconditioning effect, confirming their essential role in the tolerance mechanism. The precise composition of mitoKATP channels remains controversial, but they exhibit pharmacological properties similar to those formed by Kir6.x and SUR subunits and are localized to the , contributing to cardioprotection through mild uncoupling of . This opening increases mitochondrial volume and proton leak, generating low levels of (ROS) that act as signaling molecules to activate prosurvival pathways, such as and RISK (reperfusion injury salvage kinase), without causing oxidative damage. Studies showed that selective mitoKATP openers mimic preconditioning by preserving this ROS-mediated protection, highlighting their distinct yet complementary role to sarcKATP. Genetic evidence from Kir6.2 mice underscores the indispensability of KATP channels in cardiovascular , as these animals exhibit impaired preconditioning and heightened susceptibility to metabolic stress following ischemia-reperfusion compared to wild-type controls, directly attributing cardioprotective effects to Kir6.2-containing channels. This confirms that loss of KATP functionality exacerbates ischemic injury by disrupting both sarcolemmal and mitochondrial protective mechanisms.

Roles in Other Tissues

In neuronal tissues, ATP-sensitive potassium (KATP) channels composed of the SUR1 and Kir6.2 subunits play a critical role in maintaining membrane hyperpolarization to prevent hyperexcitability during metabolic stress. These channels open in response to decreased ATP levels and increased ADP/ATP ratios, stabilizing the neuronal membrane potential and reducing calcium influx, thereby mitigating excitotoxic damage. In the context of ischemic stroke, activation of neuronal SUR1/Kir6.2 channels confers neuroprotection by mimicking ischemic preconditioning, which limits infarct size and neuronal injury in animal models of middle cerebral artery occlusion. For instance, pharmacological openers like diazoxide reduce neuronal damage, while genetic knockout of Kir6.2 exacerbates ischemic outcomes. In vascular smooth muscle, KATP channels formed by SUR2B and Kir6.1 subunits regulate vascular tone and promote , particularly under conditions of metabolic demand. These channels exhibit low sensitivity to ATP inhibition and are activated by nucleoside diphosphates, leading to efflux, membrane hyperpolarization, and relaxation of cells to increase blood flow. , a well-known channel opener, targets SUR2B/Kir6.1 channels to induce , as evidenced by its hypotensive effects and confirmed in models where pinacidil-induced relaxation is abolished. This mechanism underscores their role in peripheral control and . Skeletal muscle expresses KATP channels primarily composed of SUR2A and Kir6.2 subunits, which contribute to fatigue resistance by coupling metabolic status to excitability during prolonged activity. Under conditions of energy depletion, these channels open to hyperpolarize the , shortening duration and limiting calcium entry, thereby conserving ATP and preventing contractile failure. Studies in models demonstrate that disruption of Kir6.2 expression enhances peak during fatigue protocols but may reduce overall exercise , highlighting a protective in maintaining muscle performance. Loss-of-function mutations in SUR2A, as seen in ABCC9-related syndromes, impair this fatigue adaptation, leading to . In hair follicles, KATP channel activation by promotes growth through prolongation of the anagen phase and stimulation of synthesis. sulfate, the active metabolite, opens follicle-expressed KATP channels (including Kir6.2/SUR1 variants), leading to increased production, which enhances follicular proliferation and expression. This mechanism shifts hair cycles toward sustained growth, as topical application shortens telogen duration and enlarges follicle size in human and animal models. Recent assessments confirm that -mediated effects are central to 's in treating alopecia, independent of systemic .

Pathophysiological Implications

Genetic Channelopathies

Genetic channelopathies associated with ATP-sensitive potassium (KATP) channels arise from mutations in genes encoding the channel subunits, primarily ABCC8 (SUR1), KCNJ11 (Kir6.2), ABCC9 (SUR2), and KCNJ8 (Kir6.1), leading to altered channel function and multisystem disorders. These inherited conditions typically manifest as loss-of-function or gain-of-function defects, disrupting metabolic sensing and cellular excitability in tissues like the pancreas, heart, and vasculature. Loss-of-function mutations predominate in pancreatic beta cells, causing constitutive channel closure, while gain-of-function variants enhance channel activity, often with tissue-specific effects. Congenital hyperinsulinism () is primarily caused by biallelic loss-of-function in ABCC8 or KCNJ11, which encode the pancreatic SUR1/Kir6.2 channel, resulting in reduced KATP conductance, beta-cell depolarization, and unregulated insulin secretion that leads to severe . These often impair channel , trafficking to the , or ATP sensitivity, with recessive inheritance common in severe cases requiring if unresponsive to medical therapy. For instance, certain missense in SUR1, such as those affecting the N-terminal region, reduce surface expression by disrupting export, exemplifying trafficking defects that abolish functional channels. In contrast, permanent neonatal mellitus results from heterozygous gain-of-function in KCNJ11, encoding Kir6.2, which decrease ATP-dependent inhibition and increase channel open probability, preventing glucose-induced closure and insulin release. The V59M substitution in Kir6.2, located in the cytoplasmic , exemplifies this by reducing ATP binding affinity and elevating basal KATP currents in beta cells, sufficient to cause from birth when expressed heterologously. These often respond to therapy, which closes the hyperactive channels, highlighting their mechanistic basis in impaired metabolic gating. Cantú syndrome, a rare multisystem disorder, stems from gain-of-function mutations in ABCC9 (SUR2) or KCNJ8 (Kir6.1), leading to excessive KATP activity in vascular and cardiac cells, which promotes , fluid retention, and . Affected individuals exhibit congenital , macrosomia, , and pericardial effusions, with symptoms linked to enhanced channel sensitivity to Mg-nucleotides or reduced ATP inhibition. The R1186Q variant in SUR2, a missense change in the nucleotide-binding domain, increases channel open probability and , contributing to the syndrome's cardiovascular and skeletal features as confirmed in functional studies and patient cohorts. These mutations exhibit dominant inheritance and variable expressivity. Loss-of-function mutations in ABCC9 have been linked to , where variants disrupt catalytic gating of cardiac KATP channels (Kir6.2/SUR2A), leading to abnormal ATP hydrolytic cycles, reduced channel inhibition, and impaired cardiac function. Identified in families with non-ischemic as of 2004, these mutations highlight SUR2's role in cardiac excitability. Additionally, biallelic loss-of-function mutations in ABCC9 cause ABCC9-related and syndrome (AIMS), a rare autosomal recessive characterized by mild to moderate , skeletal , , similar facial features, and brain abnormalities such as hypoplasia of the . First reported in 2019, AIMS arises from impaired KATP channel function in neuronal and muscle tissues, with at least nine cases described by 2024, including novel variants confirming the loss-of-function mechanism.

Involvement in Ischemic Injury

In ischemia-reperfusion scenarios, ATP-sensitive (KATP) channels exhibit paradoxical roles, where excessive opening of sarcolemmal KATP (sarcKATP) channels during the reperfusion phase contributes to ventricular arrhythmias by shortening the duration and promoting electrical instability. Selective blockers of sarcKATP channels have been shown to mitigate these reperfusion-induced arrhythmias in animal models by preventing excessive shortening, although this may come at the cost of increased intracellular calcium overload. Mitochondrial KATP (mitoKATP) channels play a dual role in reactive oxygen species (ROS) dynamics during ischemia-reperfusion injury. Mild opening of mitoKATP channels generates low levels of that act as protective signaling molecules, activating pathways such as to limit pathological production and reduce infarct size in heart models. In contrast, excessive mitoKATP activation during reperfusion can lead to pathological mitochondrial uncoupling, exacerbating the burst, promoting production, and contributing to mitochondrial dysfunction and . Aging and diabetes impair KATP channel function, worsening ischemic outcomes. In aged rat models, reduced KATP channel expression contributes to increased cardiac and diminished cardioprotection against ischemia-reperfusion injury, with pharmacological upregulation restoring function and limiting damage. Similarly, in , downregulation of Kir6.2 subunit expression decreases neuronal and vascular KATP density, impairing and exacerbating brain and cardiac ischemic damage, as observed in streptozotocin-induced diabetic models. KATP channel activity serves as a biomarker for infarct size in animal models of ischemia. In Kir6.2 knockout mice, absent KATP activation correlates with larger infarct sizes and altered ST-segment elevation compared to wild-type controls, highlighting channel function as a predictor of ischemic severity and outcome.

Pharmacology and Therapeutics

Channel Openers and Blockers

ATP-sensitive potassium (KATP) channels are modulated by a variety of pharmacological agents, including blockers and openers that target distinct subunits of the channel complex, primarily the sulfonylurea receptor (SUR) and the pore-forming Kir6 subunits. Blockers, such as , inhibit channel activity by binding to high-affinity sites on the SUR subunit, thereby closing the channel and preventing K+ efflux. For instance, glibenclamide exhibits an IC50 of approximately 0.92 nM on SUR1-containing channels when measured via whole-cell in HEK293 cells expressing Kir6.2/SUR1. Similarly, glipizide, another , shows an IC50 of 5.6 nM in inhibiting diazoxide-evoked responses in the same system. These agents demonstrate a potency rank order of glibenclamide > glipizide > tolbutamide, reflecting their interaction with the transmembrane domains of SUR1. In contrast, KATP channel openers promote channel activation, enhancing K+ conductance under conditions of metabolic stress. is a SUR1-selective opener, acting primarily on pancreatic β-cell channels with an EC50 of 31 μM in HEK293 cells expressing Kir6.2/SUR1. , a hybrid opener that also donates , exhibits selectivity for SUR2-containing channels, such as those in cardiac and vascular ; its specificity arises from interactions with residues in the 17th transmembrane helix (H17) of SUR2, including L1249 and T1253, which differ from the corresponding sites in SUR1 (T1286 and M1290). , often studied as its sulfated metabolite minoxidil sulfate, preferentially targets SUR2B isoforms found in vascular , activating Kir6.2/SUR2B channels with lower potency compared to other openers like P1075, showing minimal effects at concentrations up to 300 μM in Mg2+-free conditions. The kinetics of these agents reveal distinct affinities for channel subunits. bind with high affinity (nM range, e.g., KD = 0.9 nM for glibenclamide on SUR1 without MgATP) to sites within the ABC core transmembrane bundle of SUR1, involving key residues such as R1246 and R1300 for the sulfonyl group. In contrast, low-affinity sites (μM range) are associated with the Kir6.2 subunit, potentially involving indirect of N-terminus-SUR interactions rather than direct . Openers like and similarly favor SUR2 sites, but selectivity challenges arise; for example, 's effects in non-KATP contexts, such as hair growth, may involve indirect mechanisms like increased levels rather than direct KATP opening, as it does not activate certain K+ channels in dermal cells. These pharmacological properties underscore the structural diversity of KATP channels and the potential for subunit-specific .

Clinical Applications and Drug Development

Sulfonylureas, such as glyburide (also known as glibenclamide), have been a cornerstone in the management of type 2 diabetes since their approval by the U.S. Food and Drug Administration (FDA) in 1984. These agents close ATP-sensitive potassium (KATP) channels in pancreatic beta cells, leading to membrane depolarization, calcium influx, and enhanced insulin secretion, thereby improving glycemic control in patients with inadequate endogenous insulin response. In the treatment of severe or resistant , serves as a potent vasodilator, approved by the FDA in 1979 for this indication. By opening vascular KATP channels, hyperpolarizes cell membranes, reduces peripheral resistance, and lowers , particularly in cases unresponsive to multiple antihypertensive therapies. For congenital , a condition characterized by excessive insulin secretion leading to , is the primary medical therapy, approved by the FDA for long-term use in this disorder. As a KATP channel opener, hyperpolarizes beta cells, suppresses insulin release, and stabilizes blood glucose levels, with meta-analyses confirming its efficacy in responsive cases while noting the need for monitoring due to potential side effects like fluid retention. Emerging clinical applications of KATP-targeted therapies include cardioprotection with , a hybrid nitrate-KATP opener approved for in several countries, which reduces major coronary events in stable patients as demonstrated by the Impact of in (IONA) trial involving over 5,000 participants. Additionally, low-dose oral is gaining traction off-label for androgenetic alopecia, leveraging its KATP-opening mechanism to promote hair growth, with post-2022 studies as of 2025 emphasizing safety profiles informed by observations, where KATP gain-of-function leads to and highlights potential cardiovascular risks like . Research into for KATP channelopathies, such as those caused by ABCC8 or KCNJ11 , remains in preclinical development to address underlying genetic defects in conditions like congenital and neonatal .

References

  1. [1]
    The role of ATP-sensitive potassium channels in cellular function ...
    ATP-sensitive potassium channels (K ATP ) are widely distributed and present in a number of tissues including muscle, pancreatic beta cells and the brain.
  2. [2]
  3. [3]
    ATP-sensitive potassium channelopathies: focus on insulin secretion
    This review focuses on insulin secretory disorders, such as congenital hyperinsulinemia and neonatal diabetes, that result from mutations in K ATP channel ...Missing: paper | Show results with:paper
  4. [4]
    ATP-regulated K+ channels in cardiac muscle - PubMed
    Thus, the ATP-sensitive K+ channel seems to be important for regulation of cellular energy metabolism in the control of membrane excitability. Publication types.Missing: myocytes original paper
  5. [5]
    An Inward Rectifier Subunit Plus the Sulfonylurea Receptor | Science
    A member of the inwardly rectifying potassium channel family was cloned here. The channel, called BIR (Kir6.2), was expressed in large amounts in rat ...
  6. [6]
    Cloning of the β Cell High-Affinity Sulfonylurea Receptor - Science
    The results suggest that the sulfonylurea receptor may sense changes in ATP and ADP concentration, affect K ATP channel activity, and thereby modulate insulin ...
  7. [7]
    A family of sulfonylurea receptors determines the ... - PubMed
    We have cloned an isoform of the sulfonylurea receptor (SUR), designated SUR2. Coexpression of SUR2 and the inward rectifier K+ channel subunit Kir6.2 in ...
  8. [8]
    Mutation of the pancreatic islet inward rectifier Kir6.2 also ... - PubMed
    Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet. 1996 Nov;5( ...
  9. [9]
    KCNJ11 - ATP-sensitive inward rectifier potassium channel 11
    May 25, 2022 · This entry describes 2 isoforms produced by Alternative splicing. Q14654-1. This isoform has been chosen as the canonical sequence. All ...
  10. [10]
    Dynamic duo: Kir6 and SUR in KATP channel structure and function
    Mar 15, 2024 · Kir6 and SUR are subunits of KATP channels. Kir6 is a pore-forming subunit, and SUR regulates Kir6 activity and is essential for KATP function.Missing: selectivity filter TVMGYG
  11. [11]
    Identification of residues contributing to the ATP binding site of Kir6.2
    Intracellular ATP inhibits channel activity by binding to the Kir6.2 subunit ... Thus both N‐ and C‐termini may contribute to the ATP binding site.Missing: NC | Show results with:NC
  12. [12]
    Molecular Biology of KATP Channels and Implications for Health ...
    Kir6.2 is the major pore-forming subunit in pancreatic and cardiac cells while Kir6.1 is predominant in smooth muscle tissue. Although heteromultimerization ...
  13. [13]
    Functional Roles of Cardiac and Vascular ATP-Sensitive Potassium ...
    Two pore-forming subunits, Kir6.1 and Kir6.2, contribute to the diversity of KATP channels. To determine which subunits are operative in the cardiovascular ...
  14. [14]
    ATP-sensitive potassium currents from channels formed by Kir6 and ...
    KATP were found to be composed of 1 of 2 isoforms of the inward rectifier pore-forming subunit Kir6.1 or Kir6.2, encoded by separate genes, and 1 of 2 ...Missing: rectifying | Show results with:rectifying
  15. [15]
  16. [16]
    Is Kir6.1 a subunit of mitoKATP? - PMC - NIH
    The subunit composition of the mitochondrial ATP-sensitive K + -channel (mitoK ATP ) is unknown, though some suspect a role for the inward rectifier, Kir6.1.
  17. [17]
    Molecular Analysis of ATP-sensitive K Channel Gating and ...
    The β cell KATP channel is an octameric complex of four pore-forming subunits (Kir6.2) and four regulatory subunits (SUR1). A truncated isoform of Kir6.2 ...<|control11|><|separator|>
  18. [18]
    Structure of an open KATP channel reveals tandem PIP2 binding ...
    Mar 20, 2024 · The amino acid difference at these two positions would weaken Kir6.2-PIP2 interactions, which may explain the lower phosphoinositide head group ...
  19. [19]
    MgATP activates the ß cell KATP channel by interaction with ... - PNAS
    Sequence and hydropathy analysis suggest that SUR1 has two cytosolic nucleotide-binding domains. (NBDs) and multiple transmembrane domains (17, 18). The. NBDs ...
  20. [20]
    Dynamic Sensitivity of ATP-sensitive K+Channels to ATP
    The channel open probability (P open) is defined as an instantaneous function of [ATP] and K , ATP as follows. (Eq. 2) P open = 1 / ( 1 + ( [ ATP ] / K 1 2 , ...
  21. [21]
    Regulation of K ATP channels by P 2Y purinoceptors coupled to PIP ...
    Inhibition of KATP channel currents by extracellular ATP. Because KATP channels are known to be independent of membrane voltage (19), the voltage ramp ...
  22. [22]
    Long-chain acyl-CoA esters and phosphatidylinositol phosphates ...
    1C) with a Hill coefficient of 1.8. A plot of these Ki(ATP) values against the respective Mg2+ concentrations resulted in a concentration-response curve that ...
  23. [23]
    Phospholipids as modulators of K(ATP) channels - PubMed
    We here investigated the effects of phospholipids on the pharmacological properties of cardiac type K(ATP) (Kir6.2/SUR2A) channels. In excised membrane patches ...Missing: acyl- CoA pH temperature pinacidil Mg- nucleotides review
  24. [24]
    [PDF] Modulation of nucleotide sensitivity of ATP-sensitive potassium ...
    We re- cently showed that PIP2 dramatically reduced the sensitivity of. KATP channels to inhibition by ATP (14, 15). These observations raise the possibility ...Missing: acyl- CoA pinacidil
  25. [25]
    ATP-sensitive K+ channels and insulin secretion: their role in health ...
    Several cytosolic agents are known to modulate the ATP-sensitivity of the KATP channel, including Mg- nucleotides [23, 24], oleoyl CoA [25±28] (a metabolic ...
  26. [26]
    (PDF) Activation of ATP-sensitive potassium channels by acyl CoAs ...
    ATP-sensitive potassium (K ATP) channels are crucial to pancreatic endocrine function and their activation by acyl CoAs may disrupt hormone secretion ...
  27. [27]
    Direct activation of cloned K(atp) channels by intracellular acidosis
    Apr 20, 2001 · ATP-sensitive K(+) (K(ATP)) channels may be regulated by protons in addition to ATP, phospholipids, and other nucleotides.
  28. [28]
    Direct Activation of Cloned KATP Channels by Intracellular Acidosis
    Our data indicate that pH sensitivity is independent of ATP for the following reasons: 1) acid-induced channel activation is seen in the absence of ATP; 2) ...
  29. [29]
    Effect of temperature on the activation of myocardial KATP channel ...
    K(ATP) channel activated by nicorandil is temperature dependent and the temperature linearly related to time needed to open K(ATP) channel.Missing: modulation | Show results with:modulation
  30. [30]
    Molecular Mechanism of Sulphonylurea Block of KATP Channels ...
    Sulphonylureas inhibit channel activity by binding to SUR1. They also displace MgADP from SUR1, and consequently, ATP block at Kir6.2 is not balanced by MgATP ...
  31. [31]
    Differential roles for SUR subunits in KATP channel membrane ... - NIH
    Specifically, the sulfonylurea class of KATP channel blockers used to treat type II diabetes binds to SUR as do KATP channel openers such as pinacidil and ...
  32. [32]
    Vascular KATP channel structural dynamics reveal regulatory ...
    S8), which allows NBD dimerization, hence CFTR gating by Mg-nucleotides (55, 56). ... SUR-mediated channel stimulation by Mg-nucleotides. In the absence of MgADP ...
  33. [33]
    Structural insights into the mechanism of pancreatic K ATP channel ...
    May 19, 2022 · ATP-sensitive potassium channels (KATP) are metabolic sensors that convert the intracellular ATP/ADP ratio to the excitability of cells.
  34. [34]
    Independent Trafficking of KATP Channel Subunits to the Plasma ...
    KATP channels are unique in requiring two distinct subunits (Kir6.2, a potassium channel subunit) and SUR1 (an ABC protein) for generation of functional ...Results · Tagged Constructs Form... · Tagged Constructs Can Be...Missing: conductance | Show results with:conductance
  35. [35]
    Mutations within the P-Loop of Kir6.2 Modulate the Intraburst ...
    In this study, we have investigated the nature of the intraburst kinetics by using recombinant Kir6.2/SUR1 KATP channels heterologously expressed in Xenopus ...
  36. [36]
    Identification of two types of ATP-sensitive K+ channels in rat ...
    The single channel conductance of the large conductance KATP channels, which are formed by Kir6.2/SURs, is about 55–90 pS under symmetrical 150 mM K+ or similar ...
  37. [37]
    Physiological roles of ATP-sensitive K+ channels in smooth muscle
    K ATP channel activity may confer a voltage-independent 'brake' which limits myogenic depolarization and controls myogenic reactivity.Missing: heart | Show results with:heart
  38. [38]
    Multidimensional Regulation of Cardiac Mitochondrial Potassium ...
    Additionally, Garlid's group observed conductance values in the range of 10–30 pS [36,47]. ... mitoKATP. J. Mol. Cell. Cardiol. 2020;139:176–189. doi ...
  39. [39]
    Competitive interaction between ATP and GTP regulates ... - bioRxiv
    Jan 24, 2023 · As expected, we find that ATP dose-dependently inhibits mitoKATP activity (IC50 = 21.24 ± 1.4 mM). ... We began by testing the effects of ATP on ...Missing: IC50 | Show results with:IC50
  40. [40]
    Mitochondrial KATP channels in cell survival and death - PMC - NIH
    In this review, we attempt to highlight the recent advances in the physiological role of mitoKATP and discuss the controversies and unanswered questions.Missing: mitoKATP | Show results with:mitoKATP
  41. [41]
    Subunit composition of ATP-sensitive potassium channels ... - PubMed
    By contrast, SUR1 was not present in mitochondria. These results suggest that mitoKATP channels in rat hearts might comprise a combination of Kir6.1, Kir6.2 ...Missing: SDH 2004
  42. [42]
    Multiprotein complex containing succinate dehydrogenase confers ...
    A purified IM fraction containing these proteins was reconstituted into proteoliposomes and lipid bilayers and shown to confer mitoK ATP channel activity.Missing: association | Show results with:association
  43. [43]
    The mitochondrial ATP-dependent potassium channel (mitoK ATP ...
    Jan 17, 2024 · MitoKATP is a channel of the inner mitochondrial membrane that controls mitochondrial K+ influx according to ATP availability.
  44. [44]
  45. [45]
    Current Challenges of Mitochondrial Potassium Channel Research
    In this paper, the current challenges of mitochondrial potassium channels research were critically reviewed.
  46. [46]
    ATP-sensitive potassium channelopathies: focus on insulin secretion
    Aug 1, 2005 · This review focuses on insulin secretory disorders, such as congenital hyperinsulinemia and neonatal diabetes, that result from mutations in K ATP channel ...Missing: original paper
  47. [47]
    KATP Channels and the Metabolic Regulation of Insulin Secretion in ...
    May 19, 2023 · The KATP channel influences insulin secretion under both physiological conditions and in diabetes. A: In nondiabetic β-cells, glucose metabolism ...
  48. [48]
    KATP channels and islet hormone secretion: new insights ... - PMC
    This Review provides an introduction to the differing role of K ATP channels in insulin and glucagon secretion and considers how defective K ATP channel ...
  49. [49]
    Long-Chain Acyl–Coenzyme A Esters and Fatty Acids Directly Link ...
    It has been shown previously that LC acyl-CoA esters decrease the ATP sensitivity of pancreatic KATP channels (Kir6.1/SUR1), both in native β cells and in a ...
  50. [50]
    Regulated Expression of Adenosine Triphosphate-Sensitive ...
    Here we show that high glucose concentrations lead to a marked decrease (∼70%) in Kir6.2 messenger RNA (mRNA) levels in isolated rat pancreatic islets as well ...
  51. [51]
    Functional Regulation of KATP Channels and Mutant Insight Into ...
    Activating KATP channels shorten the action potential duration, reduce intracellular Ca2+ entry to suppress calcium overload, inhibit contractility, and ...
  52. [52]
    Role of sarcolemmal KATP channels in cardioprotection ... - NIH
    Action potential shortening due to activation of sarcKATP channels is expected to reduce the time for Ca2+ influx via L-type Ca2+ channels and to increase the ...Missing: Ca2+ | Show results with:Ca2+
  53. [53]
    KATP channels in ischaemic preconditioning - PubMed
    KATP channels in ischaemic preconditioning. Cardiovasc Res ...
  54. [54]
    Involvement of ATP-sensitive potassium channels in preconditioning ...
    Aug 7, 2025 · Article. Activation of ATP-sensitive potassium channels lowers threshold for ischemic preconditioning in dogs. December 1994 · American ...
  55. [55]
    Opening of Mitochondrial KATP Channels Triggers Cardioprotection
    In this issue of Circulation Research, Forbes et al provide a direct demonstration that opening of mitoKATP increases ROS production in isolated rat ventricular ...Missing: mitoKATP | Show results with:mitoKATP
  56. [56]
    Kir6.2 is required for adaptation to stress - PNAS
    Thus, this study identifies a physiological role for KATP channels in maintaining cardiac cellular homeostasis in the adaptive reaction to stress. Materials and ...Missing: infarct size
  57. [57]
    Knockout of Kir6.2 negates ischemic preconditioning-induced ...
    Abstract. Although ischemic preconditioning induces bioenergetic tolerance and thereby remodels energy metabolism that is crucial for postischemic recovery of ...
  58. [58]
    The role of KATP channels in cerebral ischemic stroke and diabetes
    Apr 19, 2018 · KATP channels are expressed in vascular smooth muscle, likely Kir6.1 and SUR2B subunits. Vasodilators (e.g. adenosine, calcitonin gene-related ...<|separator|>
  59. [59]
    Physiological and pathophysiological roles of ATP-sensitive K+ ...
    Kir6.1 (Inagaki et al., 1995a) and Kir6.2 (Inagaki et al., 1995c; Sakura et al., 1995) are members of the inward rectifier K+ channel family having two ...
  60. [60]
    Discovery and Characterization of VU0542270, the First Selective ...
    Vascular smooth muscle KATP channels critically regulate blood flow and blood pressure by modulating vascular tone and therefore represent attractive drug ...
  61. [61]
    ABCC9-related Intellectual disability Myopathy Syndrome is a KATP ...
    Oct 1, 2019 · In skeletal muscle, KATP channels are typically closed at rest but open in response to metabolic stress or fatigue. Channel activation ...
  62. [62]
    Disruption of KATP Channel Expression in Skeletal Muscle by ...
    A K(ATP) channel deficiency affects resting tension, not contractile force, during fatigue in skeletal muscle. Am J Physiol Cell Physiol, 279 (2000), pp ...
  63. [63]
    Minoxidil: mechanisms of action on hair growth - PubMed
    Minoxidil may also cause prolongation of anagen and increases hair follicle size. ... KATP channels are expressed in the hair follicle. A number of in vitro ...
  64. [64]
    Toxicological assessment of minoxidil: A drug with therapeutic ...
    Minoxidil also stimulates hair follicle stem cells and increases the expression of vascular endothelial growth factors and prostaglandin E2, contributing to the ...
  65. [65]
    Frontiers | KATP channel mutations in congenital hyperinsulinism
    Mar 27, 2023 · Most commonly, mutations in the coding regions alter primary sequence of SUR1 or Kir6.2. These include missense mutations and indel mutations.Missing: R15W | Show results with:R15W
  66. [66]
    Congenital Hyperinsulinism Caused by Mutations in ABCC8 Gene ...
    Most commonly, CHI is the consequence of loss-of-function (LOF) mutations in the ABCC8 (SUR1) and KCNJ11 (Kir6.2) genes located on chromosome 11p15.1, which ...
  67. [67]
    Congenital hyperinsulinism associated ABCC8 mutations that cause ...
    Many mutations in SUR1 render the channel unable to traffic to the cell surface, thereby reducing channel function. Previous studies have shown that for some ...
  68. [68]
    Activating Mutations in the Gene Encoding the ATP-Sensitive ...
    The beta-cell KATP channel is an octameric complex of four pore-forming, inwardly rectifying potassium-channel subunits (Kir6.2) and four regulatory ...
  69. [69]
    Expression of an activating mutation in the gene encoding the KATP ...
    Expression of the V59M Kir6.2 mutation in pancreatic beta cells alone is thus sufficient to recapitulate the neonatal diabetes observed in humans. beta-V59M ...
  70. [70]
    KATP Channel Mutations and Neonatal Diabetes - PMC - NIH
    In 2004, heterozygous gain-of-function mutations in the KCNJ11 gene, which encodes the Kir6.2 subunit of the KATP channel, were found to cause neonatal diabetes ...
  71. [71]
    Kir6.1 and SUR2B in Cantú syndrome - PubMed - NIH
    Sep 1, 2022 · Roles for Kir6.1/SUR2 dysfunction in disease have been suggested based on studies of animal models and human genetic discoveries. In recent ...
  72. [72]
    Kir6.1 and SUR2B in Cantú syndrome - PMC - PubMed Central
    Together they generate the predominant KATP conductance in vascular smooth muscle and are the target of vasodilatory drugs. Roles for Kir6.1/SUR2 dysfunction in ...Missing: pS | Show results with:pS
  73. [73]
    An ABCC9 Missense Variant Is Associated with Sudden Cardiac ...
    Apr 27, 2023 · The TMD2 is also a common site for gain of function variants causal for Cantú syndrome [42,43]. The pathogenicity of p.R1186Q is supported ...
  74. [74]
    Gain-of-function mutations in KATP channel subunits compromise ...
    Sep 10, 2025 · Introduction: Cantú syndrome (CS) is a rare genetic disorder caused by gain-of-function (GOF) mutations in the KCNJ8 (Kir6.1) or ABCC9 (SUR2) ...
  75. [75]
    Andersen-Tawil Syndrome - GeneReviews® - NCBI Bookshelf
    Nov 22, 2004 · Andersen-Tawil syndrome (ATS) is characterized by a triad of: episodic flaccid muscle weakness (ie, periodic paralysis); ventricular arrhythmias and prolonged ...Diagnosis · Clinical Characteristics · Differential Diagnosis · ManagementMissing: Kir6 | Show results with:Kir6
  76. [76]
    Role of ATP-sensitive K+ channels in cardiac arrhythmias - PubMed
    Although selective sarcKATP-channel blockers can prevent ischemia/reperfusion-induced ventricular arrhythmias by inhibiting the action potential shortening in ...
  77. [77]
    Mitochondrial Reactive Oxygen Species at the Heart of the Matter
    May 22, 2015 · In this review, we focus on mitochondria and ROS-related mechanisms as novel targets for therapeutics in cardiovascular diseases.
  78. [78]
    Upregulation of ATP-Sensitive Potassium Channels as the Potential ...
    Jan 15, 2023 · Administration of PLP to old rats reduces cardiac fibrosis and improves cardiac function during ischemia-reperfusion and vasorelaxation responses to K ATP ...
  79. [79]
    Advances in Cardiac ATP-Sensitive K+ Channelopathies From ...
    Aug 1, 2011 · Structure and function of ventricular sarcolemmal KATP channel complexes. The pore-forming KCNJ11-encoded Kir6.2 subunit assembles with the ...
  80. [80]
    Pharmacology of human sulphonylurea receptor SUR1 and inward ...
    In this study, we have stably expressed and characterized the pharmacology of KATP channels formed by the association of. SUR1 and Kir6.2 in HEK293 cells.
  81. [81]
    Potent and selective activation of the pancreatic beta-cell type K ATP ...
    Sep 5, 2003 · ... KATP channel with a higher potency than diazoxide, by interaction with the SUR1 subunit. The high selectivity and efficacy of the compounds ...
  82. [82]
    The molecular basis of the specificity of action of K ATP channel ...
    The therapeutically important K+ channel openers (e.g. pinacidil, cromakalim, nicorandil) act specifically on the SUR2 muscle isoforms but, except for ...
  83. [83]
    Binding and effect of KATP channel openers in the absence of Mg2+
    Openers of ATP-sensitive K+ channels (KATP channels) are thought to act by enhancing the ATPase activity of sulphonylurea receptors (SURs), the regulatory ...
  84. [84]
    Glibenclamide binding to sulphonylurea receptor subtypes - NIH
    Glibenclamide elicits these different effects by blocking ATP-sensitive K+ channels (KATP channels) in the cell membrane. KATP channels are closed by ...
  85. [85]
    Anti-diabetic drug binding site in a mammalian KATP channel ... - eLife
    Oct 16, 2017 · Sulfonylureas are anti-diabetic medications that act by inhibiting pancreatic KATP channels composed of SUR1 and Kir6.2.
  86. [86]
    Effect of minoxidil sulfate and pinacidil on single potassium channel ...
    They have suggested that cultured dermal papilla cells respond to minoxidil via a complex mechanism involving SUR2B receptors and adenosine A1 and A2 receptors.
  87. [87]
    Glyburide - StatPearls - NCBI Bookshelf
    Jun 16, 2023 · Glyburide, or glibenclamide, is a second-generation sulfonylurea approved by the Food and Drug Administration (FDA) for treating type 2 diabetes.Continuing Education Activity · Indications · Administration · Adverse Effects
  88. [88]
    Sulfonylureas in the Current Practice of Type 2 Diabetes Management
    In brief, SUs stimulate the release of insulin from the β cells of the pancreatic islets via closure of the adenosine triphosphate (ATP)-sensitive potassium (K ...
  89. [89]
    Minoxidil - StatPearls - NCBI Bookshelf
    Feb 24, 2023 · Minoxidil exerts its antihypertensive effect by opening adenosine triphosphate (ATP)-sensitive potassium channels, thereby reducing peripheral ...Missing: KATP | Show results with:KATP
  90. [90]
    Minoxidil: An Underused Vasodilator for Resistant or Severe ...
    Minoxidil is a direct vasodilator introduced in the early 1970s for the treatment of hypertension. It is capable of reducing blood pressure in most persons ...
  91. [91]
    Long-term medical treatment in congenital hyperinsulinism
    Nov 25, 2015 · Diazoxide is a KATP-channel opener and the only drug approved by the Food and Drug Administration (FDA) for long-term treatment of ...
  92. [92]
    Efficacy and safety of diazoxide for treating hyperinsulinemic ... - NIH
    This meta-analysis suggested that diazoxide was potentially useful in HH management; however, it had some side effects, which needed careful monitoring.
  93. [93]
    Characterization and Management of Adverse Events of Low-Dose ...
    The aim of this article was to comprehensively review the AEs of LDOM treatment, describing their frequency, risk factors, affected anatomical sites, and ...3. Hypertrichosis · 4. Blood Pressure · 7. Pericardial Effusion And...<|separator|>
  94. [94]
    Personalized Therapeutics for KATP-Dependent Pathologies
    Jan 20, 2023 · Mutations in the ABCC8 gene encoding the SUR1 subunit of the KATP channel cause transient neonatal diabetes, permanent neonatal diabetes or ...